Intralipid Dosing and Monitoring in Adult TPN
For adults receiving TPN, initiate Intralipid 20% at 0.5 mL/minute for 15-30 minutes as a test dose, then increase to 1 mL/minute if tolerated, with a maximum daily dose of 2.5 g fat/kg body weight (not exceeding 0.1 g/kg/hour infusion rate), while monitoring serum triglycerides regularly and maintaining levels below 400 mg/dL. 1
Initiation Protocol
The FDA-approved initiation sequence is critical to detect immediate hypersensitivity reactions:
- Start at 0.5 mL/minute for the first 15-30 minutes
- Advance to 1 mL/minute if no adverse reactions occur
- Limit first day to ≤500 mL of Intralipid 20%
- Increase dose on subsequent days if well-tolerated 1
This conservative approach allows early detection of infusion-related complications before administering larger volumes.
Maximum Dosing Parameters
Daily dose ceiling: 2.5 g fat/kg body weight (equivalent to 12.5 mL/kg of Intralipid 20%) 1
Maximum infusion rate: 0.1 g/kg/hour 1
The ESPEN ICU guidelines align with this, recommending an upper limit of 1 g/kg/day with tolerance up to 1.5 g/kg/day in critically ill patients 2. However, the FDA label takes precedence for standard TPN prescribing, establishing 2.5 g/kg/day as the definitive maximum.
Intralipids should comprise ≤60% of total caloric input, with carbohydrates and amino acids providing the remainder 1. This prevents excessive lipid administration while ensuring adequate energy delivery.
Essential Monitoring Parameters
Triglyceride Monitoring (Critical)
Measure serum triglycerides before initiating TPN and regularly during therapy 3, 4:
- Reduce lipid dose if triglycerides >400 mg/dL (>4.6 mmol/L)
- Stop lipid infusion if triglycerides >1000 mg/dL (>11.4 mmol/L) 3
This is particularly important in high-risk patients: those with pre-existing hyperlipidemia, diabetes, sepsis, renal/hepatic dysfunction, or critical illness 4. These patients have impaired lipid clearance capacity mediated by lipoprotein lipase, increasing risk of hypertriglyceridemia and associated complications.
Liver Function Tests
Monitor liver enzymes (ALT, AST, alkaline phosphatase) and total bilirubin regularly 1:
- Pediatric patients receiving Intralipid >2 weeks are at risk for parenteral nutrition-associated liver disease (PNALD)
- While adult data shows no significant LFT differences between lipid types over 6 months 5, baseline and periodic monitoring remains prudent
Glucose Control
In critically ill patients, glucose infusion should not exceed 5 mg/kg/min or 50% of energy intake 2. When hyperglycemia develops, increase the lipid-to-glucose ratio rather than continuing excessive dextrose administration, which worsens insulin resistance and increases CO2 production.
Important Clinical Caveats
Account for non-nutritional lipid sources: Propofol contains 1.1 kcal/mL from lipid emulsion and must be included in total lipid calculations to avoid exceeding maximum doses 2.
Use 1.2-micron filters only - smaller pore sizes will obstruct lipid particle passage 1.
Prefer 20% over 10% formulations: The 10% concentration contains twice the phospholipid content per gram of triglyceride, which interferes with lipoprotein lipase activity and causes problematic increases in lipoprotein X and hyperlipidemia 6. The 20% formulation is better tolerated and safer.
Laboratory interference: Intralipid causes significant lipaemia that interferes with optical coagulation analyzers 7. Inform the laboratory when patients receive lipid emulsions, as high-speed centrifugation or mechanical endpoint methods may be needed for accurate coagulation testing.
Timing for essential fatty acid deficiency prevention: Administer lipid emulsions within 7 days of starting PN to prevent essential fatty acid deficiency 3. When correcting established deficiency, 8-10% of caloric input should come from lipids 1.